Evaxion A/S Sponsored ADR EVAX 深 滬
等待開盤 06-25 09:30:00 美东时间
3.38
-0.010
-0.29%
華盛通- 最 高3.55
- 今 開3.37
- 成交量 6527股
- 最 低 3.36
- 昨 收 3.39
- 總市值 2818.99万
- 52周最高 12.1499
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.2582
- 委 比 47.83%
- 總股本 834.02万
- 歷史最高 1252.00
- 量 比 0.22
- 振 幅 5.60%
- 歷史最低 2.871
- 每 手 1
- 風險率 1.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Evaxion Unveils Promising Preclinical Data for AI-Designed AML Vaccine EVX-04
Evaxion Biotech ( ($EVAX) ) has issued an announcement. On June 11, 2026, Evaxi...
06-11 18:28
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Co-Diagnostics (NASDAQ:CODX) shares rose 20.8% to $2.38 during Tuesday...
05-20 05:06
Evaxion To Present Preclinical EVX-04 AML Vaccine Data At EHA 2026, Advancing Toward Planned Clinical Trial Submission In 2H 2026
Data will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel
05-12 21:34
Evaxion Promotes Chief Scientific Officer Birgitte Rono To COO
Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, that Birgitte Rønø, its Chief Scientific Officer (CSO), will take on
04-27 20:05
美股大行评级 | 潜在涨幅33%！大小摩等9家大行上调英特尔目标价；Popular、都福集团、联合太平洋、联合租赁等获多家大行上调评级
今日重点评级关注：瑞银：维持SS&C科技"买入"评级，目标价从112美元升至115美元；Piper Sandler：维持儒博实业"超配"评级，目标价从530美元升至540美元
04-27 14:04
HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
04-24 18:32
Evaxion Showcases AI-Immunology Platform's Potential To Develop Glioblastoma Vaccines Using Novel Tumor Targets At AACR
Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can identify a
04-18 03:03
Evaxion Announces Final Patient Visit In One-Year Extension Phase 2 Trial Of Personalized Melanoma Cancer Vaccine EVX-01
EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer). In the first two years of the phase 2 trial, patients were treated with EVX-01 in combination with
04-07 20:10
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
03-09 18:17
